The stock of radiopharmaceutical specialist Lantheus Holdings (LNTH 8.84%) was a standout in the healthcare sector on Hump Day. The company saw its share price improve by almost 9% at market close, thanks to news of a shareholder-pleasing move. That gain far outpaced the S&P 500 index, which ended up closing flat on the day.
Well before market open, Lantheus announced the launch of a $250 million share repurchase program. The initiative will be in force for one year. As is typical for stock buybacks, this one will be conducted from time to time through open market purchases at management's discretion.
Lantheus isn't generally known as a buyer of its own stock, which is one reason for the upbeat -- and likely somewhat surprised -- investor reaction. Over the trailing five years, it has only enacted repurchases in 2022, when it spent a comparatively modest $75 million on the activity.
In the press release trumpeting the new move, the specialized pharmaceutical company quoted CEO Brian Markison as saying, "With our strong financial position and the Board's commitment to shareholder value, this share repurchase program reflects our confidence in Lantheus' continued radiopharmaceuticals leadership and ability to drive long-term, sustainable growth."
Markison added that the buybacks would commence this quarter. He did not get more specific.
While Lantheus' news is certainly encouraging, no investor should lose sight of the fact that share repurchases do not a company make. Yes, they're a sign that a business is in good health. However, no stock-watcher should rely only on its level of buybacks. Fundamentals matter much more. Happily, in Lantheus' case, the company has been doing rather well lately, posting top-line growth and bottom-line profitability.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。